CD19 and lymphoma: In a xenograft mouse model of lymphoma, the resulting CD19.E28Z CAR-T cells, while producing significantly lower levels of cytokines (IL-2, IFN-γ, TNF-α), had an increased proliferative capacity and a greater ability to suppress tumor growth than cells with control CARs developed by James N. Kochenderfer in his well-known work (57).